Ladylift Non-ablative Laser Technology for the Treatment of Menopausal Vestibulodynia and Genitourinary Syndrome

Overview

Journal Prz Menopauzalny

Publisher Termedia

Date 2023 Jan 27

PMID 36704770

Authors

Guglielmo Stabile

Maria Sole Scalia

Stefania Carlucci

Francesco De Seta

Affiliations

Soon will be listed here.

Abstract

Introduction: Genitourinary syndrome of menopause (GSM) affects up to 48% of pre-menopause women and up to 90% of menopausal women. Many menopausal women with dyspareunia have significant vestibular tenderness due to oestrogen deficiency, which increases the density of sensory nerve fibres in the vulva and the vagina. For this reason, GSM is recognized as one of the causes of provoked vestibulodynia. Few therapies have proven to be effective for provoked vestibulodynia. Many studies have shown the efficacy of laser CO therapy, proving its cost-effectiveness and safety for vaginal health.

Material And Methods: In this article we tested a new non-ablative solid-state laser: Ladylift®. The main difference between Ladylift® and other laser technologies is the use of a non-ablative laser wavelength of 1470 nm, without causing ablative thermal injury on the surface of the mucosa. We enrolled 18 post- menopausal women presenting to a private clinic with GSM symptoms and provoked vulvodynia.

Results: The treatment protocol consists of 4 sessions of laser, 2 weeks apart, of the duration of 4 minutes. Benefits to menopause symptoms, reported with a numeric rating scale, and to epithelium trophism reported with the vaginal health index were apparent since the first session. Patients undergoing laser therapy have had evident benefit both from the point of view of pain and from that of vaginal health.

Conclusions: All the women tolerated the therapy well without any adverse effects. However, the beneficial effect tended to gradually decrease over time, suggesting the need to perform more therapy sessions.

Citing Articles

Combined clinical and radiological remission of rectovaginal fistulas using fractional CO2 vaginal laser: a case series and medium-term follow-up.

Drumond D, Conde C, Chebli J, Chebli L, Esperanca S, de Gois Speck N BMC Res Notes. 2023; 16(1):371.

PMID: 38115124 PMC: 10729484. DOI: 10.1186/s13104-023-06666-8.

Effects of Non-Ablative Solid-State Vaginal Laser (SSVL) for the Treatment of Vulvovaginal Atrophy in Breast Cancer Survivors after Adjuvant Aromatase Inhibitor Therapy: Preliminary Results.

Lubian-Lopez D, Butron-Hinojo C, Menjon-Beltran S, Gonzalez-Mesa E, Tapiador-Albertos S, Rodriguez-Jimenez B J Clin Med. 2023; 12(17).

PMID: 37685736 PMC: 10488849. DOI: 10.3390/jcm12175669.

New Topical Therapy for Provoked Vestibulodynia: Improvement of Psychological and Sexual Well-Being.

De Seta F, Ianniello P, Carlucci S, Nappi L, Sorrentino F, Stabile G Int J Environ Res Public Health. 2023; 20(3).

PMID: 36767294 PMC: 9915117. DOI: 10.3390/ijerph20031931.

References

Photiou L, Lin M, Dubin D, Lenskaya V, Khorasani H . Review of non-invasive vulvovaginal rejuvenation. J Eur Acad Dermatol Venereol. 2019; 34(4):716-726. DOI: 10.1111/jdv.16066. View

Rabley A, OShea T, Terry R, Byun S, Moy M . Laser Therapy for Genitourinary Syndrome of Menopause. Curr Urol Rep. 2018; 19(10):83. DOI: 10.1007/s11934-018-0831-y. View

Murina F, Karram M, Salvatore S, Felice R . Fractional CO Laser Treatment of the Vestibule for Patients with Vestibulodynia and Genitourinary Syndrome of Menopause: A Pilot Study. J Sex Med. 2016; 13(12):1915-1917. DOI: 10.1016/j.jsxm.2016.10.006. View

Gambacciani M, Palacios S . Laser therapy for the restoration of vaginal function. Maturitas. 2017; 99:10-15. DOI: 10.1016/j.maturitas.2017.01.012. View

Hawker G, Mian S, Kendzerska T, French M . Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S240-52. DOI: 10.1002/acr.20543. View

Nappi R, Martini E, Cucinella L, Martella S, Tiranini L, Inzoli A . Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019; 10:561. PMC: 6712495. DOI: 10.3389/fendo.2019.00561. View

Behnia-Willison F, Sarraf S, Miller J, Mohamadi B, Care A, Lam A . Safety and long-term efficacy of fractional CO laser treatment in women suffering from genitourinary syndrome of menopause. Eur J Obstet Gynecol Reprod Biol. 2017; 213:39-44. DOI: 10.1016/j.ejogrb.2017.03.036. View

Cruz V, Steiner M, Pompei L, Strufaldi R, Fonseca F, Santiago L . Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause. 2017; 25(1):21-28. DOI: 10.1097/GME.0000000000000955. View

Pagano T, Travaglino A, Raffone A, Vallone R, Buonfantino C, De Rosa P . Fractional Microablative CO Laser-Related Histological Changes on Vulvar Tissue in Patients With Genitourinary Syndrome of Menopause. Lasers Surg Med. 2020; 53(4):521-527. DOI: 10.1002/lsm.23311. View

10.

De Seta F, Stabile G, Antoci G, Zito G, Nappi R . Provoked Vestibulodynia and Topical Treatment: A New Option. Healthcare (Basel). 2022; 10(5). PMC: 9142053. DOI: 10.3390/healthcare10050830. View

11.

Li J, Li H, Zhou Y, Xie M, Miao Y, Wang L . The Fractional CO Laser for the Treatment of Genitourinary Syndrome of Menopause: A Prospective Multicenter Cohort Study. Lasers Surg Med. 2020; 53(5):647-653. PMC: 8246931. DOI: 10.1002/lsm.23346. View

12.

Wallace S, St Martin B, Lee K, Sokol E . A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia. Am J Obstet Gynecol. 2020; 223(6):890.e1-890.e12. DOI: 10.1016/j.ajog.2020.06.032. View

13.

Friedrich Jr E . Vulvar vestibulitis syndrome. J Reprod Med. 1987; 32(2):110-4. View

14.

Rosen N, Dawson S, Brooks M, Kellogg-Spadt S . Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches. Drugs. 2019; 79(5):483-493. DOI: 10.1007/s40265-019-01085-1. View

15.

Berger M, Messore M, Pastuszak A, Ramasamy R . Association Between Infertility and Sexual Dysfunction in Men and Women. Sex Med Rev. 2016; 4(4):353-365. DOI: 10.1016/j.sxmr.2016.05.002. View

16.

Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi R, Simon J . Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas. 2015; 82(3):308-13. DOI: 10.1016/j.maturitas.2015.07.020. View

17.

Arroyo C . Fractional CO laser treatment for vulvovaginal atrophy symptoms and vaginal rejuvenation in perimenopausal women. Int J Womens Health. 2017; 9:591-595. PMC: 5584900. DOI: 10.2147/IJWH.S136857. View

18.

Palacios S, Nappi R, Bruyniks N, Particco M, Panay N . The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric. 2018; 21(3):286-291. DOI: 10.1080/13697137.2018.1446930. View

19.

Sokol E, Karram M . Use of a novel fractional CO2 laser for the treatment of genitourinary syndrome of menopause: 1-year outcomes. Menopause. 2017; 24(7):810-814. DOI: 10.1097/GME.0000000000000839. View

20.

Lev-Sagie A, Kopitman A, Brzezinski A . Low-Level Laser Therapy for the Treatment of Provoked Vestibulodynia-A Randomized, Placebo-Controlled Pilot Trial. J Sex Med. 2017; 14(11):1403-1411. DOI: 10.1016/j.jsxm.2017.09.004. View